企業プロフィール
Madrigal 株価・ニュース・カタリスト
- ティッカー:
- MDGL
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
524.87 USD (+3.41%)
終値
最終更新: 2026年8月17日
10.4B USD
時価総額
株価変動の要因
As of Aug 17, 2026, MDGL closed up 3.41% at $524.87. No new same-company headline was identified in the current news window.
企業概要
Commercial MASH Leader
Madrigal Pharmaceuticals is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis, or MASH. Its lead product, Rezdiffra, is a once-daily oral liver-directed THR-beta agonist and the first medicine approved by both the FDA and European Commission for MASH with moderate to advanced fibrosis.
Rezdiffra Growth Platform
Rezdiffra is the company's commercial foundation. Second-quarter 2026 net sales reached $364.3 million, up 71% year over year, and more than 49,000 patients were on therapy as of June 30, 2026. Madrigal is investing in field-force expansion, disease education, real-world evidence, and physician adoption to maximize the long-term value of the launch.
Pipeline Anchored by Combination Therapy
Madrigal is building beyond Rezdiffra through MGL-2086, an oral small-molecule GLP-1 receptor agonist and orforglipron derivative. The company initiated Phase 1 dosing in June 2026 as part of a strategy to develop once-daily oral combination treatments for MASH anchored by Rezdiffra.
Strategic Position
Madrigal is best understood as a commercial-stage MASH company with a foundational therapy and a strategy to defend leadership through IP, evidence generation, and combination development. Its differentiation rests on Rezdiffra's first-mover position, expanding patient base, and potential to address both liver and cardiometabolic risk.
今後のカタリスト
- Phase 1 safety and dose-response evaluation for MGL-2086 after first dosing in June 2026.
- Future data from the Phase 3 outcomes trial of Rezdiffra in compensated MASH cirrhosis.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。